BioCryst Pharmaceuticals, Inc.

KalVista’s announcement on June 13 that the US Food and Drug Administration would not approve Ekterly (sebetralstat), its oral plasma kallikrein inhibitor for treatment of hereditary angioedema (HAE),

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear

The US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti

There are pivotal moments that stick in the mind of any longtime CEO. Some are good, some are bad, all are memorable. For Bill Burns, three defining snapshots encapsulate the highs and lows of his nin